Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Representing polarized light in computer models
DRAM refresh method and system
Secure device sharing
Second order correction circuit and method for bandgap voltage reference
Method of monitoring and configuring
Shoe bag
Reading apparatus and reading method
  Randomly Featured Patents
Electrical connector fastened to a rigid member for improved connector rigidity
Lysosomal targeting of immunogens
Thermal protection for a heated fuel injector
Container body portion
Member with a cleaning surface and a method of removing contamination
Ultrafine iron-containing rutile titanium oxide and process for producing the same
Silicone/zirconium ball for use in a cursor control device
Method for making shaped filtration articles
Shift register and display device using the same
Barrier plate for highways